NovaBay Pharmaceuticals to Hold 2017 Fourth Quarter and Full Year Conference Call on March 20, 2018

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report 2017 fourth quarter and full year financial results after market close on Tuesday, March 20. Management will hold an investment community conference call that day to discuss financial results and provide a Company update.

    
      
        
        
        
           
        
        
           
        
        
        
      
      
        
          DATE:
        
        
        
        
        
        
          Tuesday, March 20
        
      
      
        
          TIME:
        
        
        
        
        
        
          4:30 p.m. ET / 1:30 p.m. PT
        
      
      
        
          DIAL IN:
        
        
        
        
        
        
          800-608-8202 from within the U.S.
        
      
      
        
        
        
        
        
        
        
          702-495-1913 from outside the U.S.
        
      
      
        
        
        
        
        
        
        
          Enter conference identification number 68570527
        
      
      
        
        
        
        
        
        
        
           
        
      
    
    

The live call also will be available at http://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Pacific time April 20, 2018, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 2764067. The call will also be archived at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Socialize and Stay informed on NovaBay’s progress:Like us on FacebookFollow us on TwitterConnect with NovaBay on LinkedInJoin us on Google+Visit NovaBay’s Website

NovaBay ContactsFor NovaBay Avenova purchasing information:Please Call us toll free: 1-800-890-0329 or email [e-mail]

View source version on businesswire.com: http://www.businesswire.com/news/home/20180221005416/en/

NovaBay Pharmaceuticals, Inc.Jack McGovernChief Financial [e-mail] ContactLHA Investor RelationsJody [e-mail]